1 Recommendations

1.1 Alirocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:

  • Low‑density lipoprotein concentrations are persistently above the thresholds specified in table 1 despite maximal tolerated lipid‑lowering therapy. That is, either the maximum dose has been reached or further titration is limited by intolerance (as defined in NICE's guideline on familial hypercholesterolaemia: identification and management).

  • The company provides alirocumab with the discount agreed in the patient access scheme.

  • National Institute for Health and Care Excellence (NICE)